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muscle relaxants and botulinum toxin.2 Botulinum toxin
type A improves the gait outcomes and the overall progno-
sis in children with cerebral palsy.3 However, its duration
of effect varies. The use of intramuscular botulinum toxin
for focal spasticity may also increase the efficacy of orally
administered drugs such as baclofen or tizanidine.4
Various oral medications have been used to diminish
the sensitivity of local nerves and muscles to control their
reactions to environmental stimuli that result in muscle
overactivity or involuntary movements.5 Baclofen, tizani-
dine, and diazepam are the most frequently prescribed
oral agents. Tizanidine is a centrally acting α-2 adrener-
gic agonist. It has been shown to decrease polysynaptic
reflex activity, probably by reducing release of excitatory
neurotransmitters from presynaptic neurons. Baclofen
acts centrally like most anti-spasticity medications. It
binds to γ-aminobutyric acid (GABA) receptors and
inhibits spinal reflexes. Both medications have been
found to be effective in the treatment of spasticity of both
cerebral and spinal origin among adult patients. The use
of oral medications in children with cerebral palsy has not
been thoroughly studied. Higher dosages are associated
with systemic side effects such as sedation, weakness,
and behavior change.6 The purpose of this study was to
compare the effectiveness of baclofen and tizanidine in
Cerebral palsy is characterized by nonprogressiveimpairment of posture and motor function. Mostoral medications used to treat the spasticity of
cerebral palsy have been inadequately studied in children,
and these drugs offer only a modest benefit because of
undesirable side effects.
Abnormal motor function and spasticity are key fea-
tures in children with cerebral palsy. Spasticity manage-
ment requires the use of different treatment methods
throughout the childhood.1 For the walking child with
spastic cerebral palsy, simple measures such as stretching,
walking, and orthotic use can be supplemented by oral
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children receiving intramuscular botulinum type A for
spasticity.
Patients and Methods
We retrospectively reviewed 30 children with gastrocne-
mius spasticity who were evaluated at Gaziantep
University Hospital, Turkey, between 2005 and 2007. All
of these children had spastic equinus foot deformity asso-
ciated with cerebral palsy or static encephalopathy con-
firmed by a pediatric neurologist.
All patients were enrolled in a rehabilitation program and
given local injections of botulinum type A for spasticity.
Selection criteria for intramuscular botulinum type A injec-
tions included dynamic deformity interfering with function,
producing pain, or contributing to progressive deformity;
painful spasticity with or without fixed muscle contracture.7
We injected 20 to 24 U of botulinum type A (Botox, Allergan
Pharma, Irvine, CA) per kilogram of body weight with a max-
imum of 300 U per child on 1 occasion with a maximum
dose of 50 U per injection site.8 Intranasal midazolam was
used as an anesthetic agent during the procedure.9
A 1:1 dilution of botulinum toxin and normal saline
was used. We palpated the gastrocnemius muscle, using
the skin as a fulcrum to determine needle placement
without electromyography guidance. The short 1-mL
“diabetic” all-in-one syringe and needle were used for this
purpose. Both gastrocnemius muscles were injected with
botulinum type A at each injection session.
A total of 17 children were treated with adjuvant oral
baclofen and 13 received oral tizanidine. The tizanidine
dosage ranged from 0.3 mg/kg/day to 0.5 mg/kg/day in 4
divided doses.10 The baclofen dosage ranged from 10
mg/kg/day to 15 mg/kg/day in 3 divided doses to a maxi-
mum of 40 mg/day if less than 8 years of age or to 60
mg/day if more than 8 years of age.11 The patients were not
randomized, and the decision to chose one medication or
the other was entirely based on physician preference.
The treatment protocol was approved by the hospital’s
ethical committee, and an informed consent was obtained
from the patients or guardians. All parents were asked to fill
out “caregiver questionnaire” form (CHQ)12 and to docu-
ment the side effects from tizanidine or baclofen before
and for 3 months after the botulinum type A injections.
All patients were followed at 2- to 4-week intervals and
evaluated for a total of 12 weeks. The therapeutic
response in both the groups was assessed by means of
Gross Motor Functional Measurement (GMFM)13 and
the modified Ashworth scale (MAS)14 for leg functional
measurement and for leg spasticity assessment by the
same pediatric neurologist. Laboratory tests (done
monthly) included complete blood count and differential,
liver function tests, thyroid function test, electrolytes,
serum glucose, lipid, and albumin level.
Statistical Analysis
Data were analyzed using a commercially available soft-
ware package for social science SPSS (Release 14.0, stan-
dard version, copyright © SPSS; 1989-2002). Proportions
were compared using the χ2 test or Fisher exact test,
where appropriate, and means were compared using
Student t test. Probability values were two-tailed.
Significance level was set at 5%.
Results
Thirty children were included in the study. Age ranged
from 2 years to 14 years (mean; 5.6 years), and 20 (66%)
participants were male. A total of 17 children (57%) were
treated with oral baclofen and 13 (43%) received oral
tizanidine. The 2 groups were similar in age, sex, and
mean GMFM, MAS, and CHQ scores. Baseline charac-
teristics of both groups are given in Table 1.
The mean scores of both the GMFM (76.63 ± 5.88 vs
68.17 ± 1.99; P < .001) and the CHQ (70.23 ± 4.76 vs
66.59 ± 3.53; P = .03) for the tizanidine group were sig-
nificantly higher than those of the baclofen group (Table 2).
Significant improvements in the CHQ score (2.24 ± 0.56)
occurred in baclofen group (P = .03).
Side effect profile was also slightly better for the
tizanidine treatment group. Patients treated with baclofen
had more complains of anorexia and abdominal pain than
the tizanidine-treated patients.
Table 1. Baseline Clinical Characteristics of
the Treatment Groups 
Baclofen Tizanidine P
Group Group Value
Sex: male/female; n (%) 11/6 (64/36) 9/4 (69/31) .55
Age: mean ± SD 5.71 ± 2.97 5.46 ± 2.63 .81
GMFM score: mean ± SD 46.04 ± 2.73 47.40 ± 1.51 .09
MAS score: mean ± SD 3.65 ± 0.60 3.69 ± 0.48 .82
CHQ score: mean ± SD 57.82 ± 3.76 58.08 ± 3.68 .85
GMFM, Gross Motor Function Measure; MAS, Modified Ashworth Scale; CHQ,
Caregiver Questionnaire; SD, standard deviation. 
Table 2. Clinical Outcome of the Treatment
Groups After 3 Months
Baclofen Tizanidine P
Group Group Value
GMFM score: mean ± SD 68.17 ± 1.99 76.63 ± 5.88 < .001
MAS score: mean ± SD 2.24 ± 0.56 1.77 ± 0.59 .03
CHQ score: mean ± SD 66.59 ± 3.53 70.23 ± 4.76 .03
GMFM, Gross Motor Function Measure; MAS, Modified Ashworth Scale; CHQ,
Caregiver Questionnaire; SD, standard deviation.
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Discussion
This study compared the efficacy and safety of oral
baclofen and tizanidine when used in conjunction with
botulinum toxin type A for cerebral palsy. Our data sug-
gest that adjuvant treatment with oral tizanidine is more
effective than baclofen in combination with botulinum
toxin for spastic equinus foot deformity due to cerebral
palsy. Significant improvement was demonstrated using
GMFM and the MAS (P ≤ .05). The side-effect profile of
tizanidine was superior to that of baclofen.
Botulinum toxin injections are currently a standard
treatment for spastic cerebral palsy, but there is currently
no consensus among clinicians about its optimal dose.
There are no standard guidelines for dosing botulinum
toxin type A in children. Reviews of previous publications
indicate that the dose used for children with cerebral
palsy has increased over time. Dosages of 16 U/kg to 24
U/kg body weight are now widely used. The current prac-
tice is to inject several muscles at each injection session,
with smaller patients receiving higher doses than reported
in the past.8
Another important confounding variable is the exten-
sive use of physical and occupational therapy in the man-
agement of these children. As controversial as it may
sound, there is limited formal evidence to establish the
real benefit of these therapies in the rehabilitation of
focal muscle spasticity.15
The important limitation of this study is the limited
number of the sample size and its nonrandomized
approach. Adjunctive treatment is required in several
patients with spasticity in addition to botulinum injec-
tions. Nevertheless, these findings may have important
clinical implications for physicians who treat children
with cerebral palsy. Larger, prospective, randomized, con-
trolled clinical trials in the pediatric population are
needed to confirm and extend our findings.
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